Floatz Rating
C36/100
Confidence
Indicative
Sponsor
Universitair Ziekenhuis Brussel
Modality
radiopharmaceutical
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
21Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04758650CT.gov Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68ganota-anti-mmr-vhh2 (this asset) | Universitair Ziekenhuis Brussel | P2 | C · 36 |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Bleomycin | National Cancer Institute (NCI) | P4 | BBB |
| Adriamycin | M.D. Anderson Cancer Center | P4 | BBB |
| Dacarbazine | M.D. Anderson Cancer Center | P4 | BBB |
| Methotrexate | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P3 | BB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for 68ganota-anti-mmr-vhh2
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Cancer | — | P2 | C · 36 |
| Carotid Stenosis | — | P2 | C · 36 |
| Atherosclerosis | — | P2 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68ganota-anti-mmr-vhh2 in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/68ganota-anti-mmr-vhh2-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →